[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
Invited Commentary
Practice Gaps
April 2015

Promoting Safe Use of Isotretinoin by Increasing Contraceptive Knowledge

Author Affiliations
  • 1Ronald O. Perelman Department of Dermatology, New York University, New York
JAMA Dermatol. 2015;151(4):393-394. doi:10.1001/jamadermatol.2014.4158

Isotretinoin is a rewarding medication to prescribe. With an efficacy rate of 60% to 85%, it is the only option that dermatologists have to offer an acne “cure.”1

Preventing pregnancies for women receiving isotretinoin is a challenging aspect of patient management. In the United States, monitoring systems such as SMART (System to Manage Accutane-Related Teratogenicity) and iPLEDGE have attempted to address this. These elaborate systems have resulted in a decrease in overall isotretinoin prescriptions and have disproportionately affected the treatment of acne in women. At Kaiser Permanente, after the implementation of iPLEDGE, prescriptions for women declined by 36% compared with 20% for men. Federal monitoring has not, however, been shown to decrease pregnancies.2

×